Archiv
Archiv anzeigen:
bis


How Can Gastric Cancer Incidence and Mortality Be Reduced?

John R. Saltzman, MD reviewing Li W-Q et al. BMJ 2019 Sep 11

A long-term study shows benefits of H. pylori eradication and supplementation with vitamins and garlic.


Direct Oral Anticoagulation vs. Warfarin for Cerebral Venous Thrombosis

Brady L. Stein, MD, MHS reviewing Ferro JM et al. JAMA Neurol 2019 Sep 3

Rates of bleeding, progressive CVT, and recurrent venous thromboembolism were similar with dabigatran or warfarin.


Treatment Outcomes Among Elderly HIV-Infected Patients with Cancer

Keith Henry, MD reviewing Coghill AE et al. JAMA Oncol 2019 Aug 1

Among cancer patients 65 years of age and older, outcomes were significantly worse among those with HIV infection.


Apixaban vs. Rivaroxaban for Acute Venous Thromboembolism

Brady L. Stein, MD, MHS reviewing Aryal MR et al. Blood Adv 2019 Aug 13

In a real-world comparison, the benefit-to-risk ratio favored apixaban with similar efficacy and lower rates of bleeding.


USPSTF Expands Guidance on BRCA-Related Genetic Counseling and Testing

Laila Samiian, MD, FACS reviewing Owens DK et al. JAMA 2019 Aug 20, Nelson HD et al. JAMA 2019 Aug 20

Update recommends that providers use a risk assessment tool for all women with personal or family history of breast and ovarian cancer.


New USPSTF Recommendations on Breast Cancer Chemoprophylaxis

Andrew M. Kaunitz, MD reviewing US Preventive Services Task Force. JAMA 2019 Sep 3, Nelson HD et al. JAMA 2019 Sep 3, Pace LE and Keating NL. JAMA 2019 Sep 3

The USPSTF recommends that providers discuss use of tamoxifen, raloxifene, or aromatase inhibitors with women at excess risk for breast cancer and low risk for adverse effects.


Nipple-Sparing Mastectomy for Invasive Breast Cancer

Henry Mark Kuerer, MD, PhD, FACS reviewing Wu Z-Y et al. JAMA Surg 2019 Aug 28

Patients undergoing the procedure with immediate breast reconstruction had a low incidence of cancer recurrence at the nipple-areola complex.


Tumor Seeding at Colonoscopy: A Cause of Metachronous Colorectal Cancer?

Charles J. Kahi, MD, MS reviewing Backes Y et al. Gastroenterology 2019 Aug 13

A small proportion of metachronous colorectal cancers could be due to seeding from colonoscopic manipulation of the primary tumor.


Comparing Colorectal Cancer Screening Modalities

Charles J. Kahi, MD, MS reviewing Grobbee EJ et al. Clin Gastroenterol Hepatol 2019 Aug 13

Programmatic, multiple-round FIT detected more neoplasia than one-time sigmoidoscopy or colonoscopy in the intention-to-screen analysis, but there is more to the story.


A New Option for Treatment-Refractory Multiple Myeloma

Michael E. Williams, MD, ScM reviewing Chari A et al. N Engl J Med 2019 Aug 22

A quarter of patients responded to the oral agent selinexor, an inhibitor of the nuclear export protein exportin 1.


Archiv
Seite von 84
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie
Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.

Kommentar weiterlesen

Apalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Smith MR et al. N Engl J Med 2018 Feb 8

Metastasis-free survival was significantly longer with apalutamide than with placebo.


Second-Line Olaparib for Gastric Cancer

David H. Ilson, MD, PhD reviewing Bang Y-J et al. Lancet Oncol 2017 Dec

Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.


Predicting Response to Immunotherapy in Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Rizvi H et al. J Clin Oncol 2018 Jan 16

Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.


Prolonged Adjuvant Aromatase Inhibitor Treatment for Early Breast Cancer

William J. Gradishar, MD reviewing Blok EJ et al. J Natl Cancer Inst 2018 Jan 1, Goldvaser H et al. J Natl Cancer Inst 2018 Jan 1, Pohlmann PR and Isaacs C. J Natl Cancer Inst 2018 Jan 1

Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.


Prognosis of Monoclonal Gammopathy of Undetermined Significance

David Green, MD, PhD reviewing Kyle RA et al. N Engl J Med 2018 Jan 18

Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.


Prognosis for BRCA-Mutated Breast Cancer

William J. Gradishar, MD reviewing Copson ER et al. Lancet Oncol 2018 Jan 11

Survival is similar between BRCA mutation carriers versus those with sporadic disease.


Electrical Field Therapy for Glioblastoma

Roy E. Strowd, MD reviewing Stupp R et al. JAMA 2017 Dec 19

Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.


Atezolizumab for Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Powles T et al. Lancet 2017 Dec 18, Massari F and Di Nunno V. Lancet 2017 Dec 18

Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.


Pembrolizumab for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Balar AV et al. Lancet Oncol 2017 Sep 26

First-line therapy demonstrated antitumor activity in a phase II study.


Restarting Adjuvant Endocrine Therapy for Breast Cancer

William J. Gradishar, MD reviewing He W et al. J Natl Cancer Inst 2017 Oct 01

Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.